Elan Touting Myobloc Manufacturing Process, Use In Botox Non-Responders
This article was originally published in Pharmaceutical Approvals Monthly
The manufacturing process for Myobloc (botulinum toxin type B) may produce a product with greater biological activity than Allergan’s competing agent Botox (botulinum toxin type A), Elan suggested in a teleconference following approval of its cervical dystonia (CD) product.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class